Abstract
Purpose To evaluate the efficacy and safety of Chinese herbal injection thoracic perfusion combined with cisplatin chemotherapy for lung cancer patients with MPE.
Method Eight databases were searched for articles published from inception to August 20, 2022 for randomized-controlled trials (RCTs) that are relevant. The included studies were reviewed by two investigators, with relevant data extracted independently. Primary outcome was identified as objective response rate (ORR), while secondary outcomes were identified as quality of life (QOL) and adverse reactions. Quality of the included trials was assessed through risk of bias assessment of the Cochrane risk-of-bias tool. The Revman5.3 and Stata17.0 software were used to calculate risk ratio (RR) at 95% confidence intervals (CI) for binary outcomes.
Results 29 RCTs involving 1887 patients were included in this study. Compared with patients treated with cisplatin thoracic perfusion alone, those with Chinese herbal injection and cisplatin thoracic perfusion had better therapeutic effects (RR=1.44, 95% CI: 1.35∼1.53, P = 0.000), higher KPS score (RR = 1.47, 95%CI: 1.34∼1.61, P = 0.0000), lower digestive tract reaction(RR = 0.56, 95%CI: 0.48∼0.67, P = 0.000), bone marrow suppression (RR = 0.50, 95% CI: 0.43∼0.59, P =0.000) and chest pain reactions (RR = 0.65, 95%CI: 0.47∼0. 89, P = 0.007).
Conclusion The systematic review indicated that Chinese herbal injection thoracic perfusion combined with cisplatin chemotherapy may improve therapeutic effect, quality of life, and reduce adverse reactions. More large-scale and higher quality RCTs are warranted to support our findings. Systematic Review Registration: PROSPERO, identifier CRD42022347345.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Bao-Jin Hua designed the research. Zhong-Ning He, Ming-Wan Su and Jie-He performed literature search. Ming-Wan Su, Jie-He, Guang-Hui Zhu, Yue LI, Shu-Lin He, Jia-Qi Hu and Yu-Wei Zhao performed article selection and data extraction. Zhong-Ning He and Guang-Hui Zhu assessed methodological bias risk. Zhong-Ning He, Ming-Wan Su and Jie-He conducted a meta-analysis. Bo-Lin Shi, Yu-Wei Zhao and Shun-Tai Chen assessed study quality. Zhong-Ning He finished the manuscript draft. Bao-Jin Hua and Shun-Tai Chen reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
↵† Zhong-Ning He, Ming-Wan Su, Jie-He Guang-hui Zhu and Yu-Wei Zhao share co-first author.
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
